|
|
Article: First Scientific Data for Lybrel(TM) Presented at ASRM Meeting.
- Article from:
- PR Newswire
- Article date:
- October 17, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Presentation of Landmark Data on Investigational Low-Dose Oral Contraceptive Designed to Stop Hormonal Fluctuations Associated With the Entire Menstrual Cycle -
MADISON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced that four scientific abstracts regarding Lybrel(TM) (0.09 mg levonorgestrel/0.02 mg ethinyl estradiol tablets) were presented for the first time today at the 61st Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Montreal, Canada. The studies investigated the effects of 0.09 mg levonorgestrel/0.02 mg ethinyl estradiol on ovarian activity, safety and efficacy, endometrial ...